Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
Completed · Phase 2
Conditions studied: Pancreatic Neoplasms
In brief
The purpose of this study is to see the effect of PEP02 in the treatment of metastatic pancreatic cancer.
Key facts
- Study ID
- NCT00813163
- Run by
- PharmaEngine
- People needed
- 41
- Starts
- 2009-01-01
- Expected to finish
- 2012-07-01
- Last updated by the study team
- 2019-09-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas
- Metastatic disease
- Documented disease progression after treatment with 1 line of prior gemcitabine-based regimen
- Karnofsky performance status equal or more than 70
You may not qualify if…
- With active CNS metastases
- With clinically significant gastrointestinal disorder (e.g., bleeding, inflammation, occlusion, or diarrhea > grade 1)
- Major surgery or radiotherapy within 4 weeks
- Prior participation in any investigational drug study within 4 weeks
- With prior irinotecan treatment
Where it is running
- Comprehensive Cancer Center, UCSF — San Francisco, California, United States
- National Health Research Institutes/National Chen-Kung Uiversity Hospital — Tainan, Taiwan
- National Taiwan University Hospital — Taipei, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.